Robert R. Olander
Known title: Chief Financial OfficerCIK: 0001988999
Robert R. Olander's purchase track record
Robert R. Olander has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/12/2024 | ALTO | $10K | +5.9% | -39.7% | -1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALTO | ▼ Sell | Tax Withholding | 41,072 | $197K | 4/1/2026 | View on chart |
| ALTO | ▲ Buy | Grant | 35,730 | $0 | 3/17/2026 | View on chart |
| ALTO | ▼ Sell | Tax Withholding | 22,128 | $25K | 4/1/2025 | View on chart |
| ALTO | ▲ Buy | Grant | 55,500 | $0 | 3/31/2025 | View on chart |
| ALTO | ▲ Buy | Open Market | 7,350 | $10K | 11/12/2024 | View on chart |
| ALTO | ▼ Sell | Tax Withholding | 15,178 | $35K | 4/1/2024 | View on chart |
| ALTO | ▲ Buy | Grant | 83,330 | $0 | 3/20/2024 | View on chart |
| ALTO | ▲ Buy | Grant | 58,500 | $0 | 9/17/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
StoneX initiates coverage on Alto Ingredients with $7 target
StoneX has begun tracking Alto Ingredients, assigning a Buy rating and a price target of $7. This new analyst view places the stock within the current 52-week range of $0.99 to $6.11. The move adds to the existing analyst consensus, which currently averages a target of $9.00 based on two estimates.
StoneX initiates coverage on Alto Ingredients with $7 target. StoneX has begun tracking Alto Ingredients, assigning a Buy rating and a price target of $7. This new analyst view places the stock within the current 52-week range of $0.99 to $6.11. The move adds to the existing analyst consensus, which currently averages a target of $9.00 based on two estimates.